$17.24
-0.29 (-1.65%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where NVCR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
15 interventional · 4 observational · 1 with posted results
Held by 13 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, AQR CAPITAL MANAGEMENT LLC, D. E. Shaw & Co., Inc., BAILLIE GIFFORD & CO, Point72 Asset Management, L.P., +8 more) · FINRA short interest 4.9 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 8 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France)NCT06924099observationalOverall Survival (OS) | — | Recruiting | — | Glioblastoma | 430 | 2029-01-31 | in 896 d | 2025-04-11 |
| TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma StudyNCT05538806observationalTime from diagnosis of pleural mesothelioma to death of any cause as median overall survival time. | — | Recruiting | Device: TTFields | Pleural Mesothelioma | 198 | Dec 2027 | ≤ 499 d | 2025-08-22 |
| Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBMNCT04471844Overall Survival (OS)Randomized · Open-label · Treatment | Not applicable | Completed | Device: Optune® | Glioblastoma Multiforme | 981 | 2026-02-19actual | — | 2026-03-30 |
| EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal AdenocarcinomaNCT06390059Disease control rate (DCR)Open-label · Treatment | Phase 2 | Completed | Device: Tumor Treating Fields · Drug: Atezolizumab, Gemcitabine, nab-paclitaxel | Metastatic Pancreatic Ductal Adenocarcinoma | 84 | 2025-11-18actual | — | 2026-04-30 |
| TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning StudyNCT04717739observationalTime of usage of TTFields treatment in follow-up derived from monitoring data of the devices, standardised to usage days, as measure of compliance with TTFields treatment. | — | Unknown status | Device: TTFields | Glioblastoma | 500 | 2024-12-01 | — | 2023-01-10 |
| Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)NCT03377491results2026-01-21Overall Survival of Subjects Treated With TTFields Concomitant With Gemcitabine and Nab-paclitaxel vs Chemotherapy AloneRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Device: NovoTTF-200T · Drug: Gemcitabine, nab paclitaxel | Pancreas Adenocarcinoma | 571 | 2024-10-16actual | — | 2026-01-21 |
| Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric AdenocarcinomaNCT04281576Objective response rateOpen-label · Treatment | Not applicable | Completed | Device: NovoTTF-100L(P) · Drug: Oxaliplatin, Capecitabine, Trastuzumab | Gastric Cancer, GastroEsophageal Cancer | 28 | 2024-06-07actual | — | 2024-11-14 |
| Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)NCT03940196Overall survivalRandomized · Open-label · Treatment | Phase 3 | Completed | Device: NovoTTF-100L(O) · Drug: Paclitaxel | Ovarian Cancer | 540 | 2023-05-18actual | — | 2024-03-29 |
| TTFields In GErmany in Routine Clinical CareNCT03258021observationalTime to death of any cause (overall survival (OS)) from diagnosis | — | Unknown status | Device: TTFields | Glioblastoma | 710 | Jun 2021 | — | 2021-01-28 |
| Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)NCT03606590Overall response rateOpen-label · Treatment | Phase 2 | Completed | Device: NovoTTF-100L(P) device · Drug: Sorafenib | Hepatocellular Carcinoma | 25 | 2021-01-14actual | — | 2024-11-14 |
| TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBMNCT03780569Safety of concomitant Radiotherapy/Temozolomide with NovoTTF-200A: The incidence of Radiotherapy treatment delays during concomitant Radiotherapy/Temozolomide/NovoTTF-200A will be documented including severity and relationship to NovoTTF-200A.Open-label · Treatment | Not applicable | Unknown status | Device: NovoTTF-200A · Radiation: Radiotherapy · Drug: Temozolomide | Glioblastoma Multiforme | 10 | Jan 2019 | — | 2018-12-20 |
| Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)NCT02397928Overall SurvivalOpen-label · Treatment | Phase 2 | Completed | Device: NovoTTF-100L device · Drug: Pemetrexed, Cisplatin or Carboplatin | Malignant Pleural Mesothelioma | 82 | Apr 2018actual | — | 2018-09-25 |
| Post-approval Study of NovoTTF-100A in Recurrent GBM PatientsNCT01756729Overall SurvivalNon-randomized · Open-label · Treatment | Phase 4 | Terminatedsponsor's stated reason: Amendment of Study Protocol | Device: NovoTTF-100A | Recurrent Glioblastoma Multiforme | 13 | Jan 2018 | — | 2016-03-02 |
| Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA)NCT01971281Adverse Events Severity and FrequencyNon-randomized · Open-label · Treatment | Phase 1/2 | Unknown status | Device: NovoTTF-100L · Drug: Gemcitabine, nab-Paclitaxel | Pancreatic Adenocarcinoma | 40 | Dec 2017 | — | 2017-09-13 |
| Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)NCT01755624Time to Local and Distant Progression in The BrainRandomized · Open-label · Treatment | Phase 2 | Unknown status | Device: NovoTTF-100A device · Other: Best Standard of Care | 1-5 Brain Metastases From Non-Small Cell Lung Cancer | 18 | Jul 2017 | — | 2016-09-21 |
| Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)NCT00916409Progression Free Survival (PFS) timeRandomized · Open-label · Treatment | Phase 3 | Completed | Device: NovoTTF-100A device · Drug: Temozolomide | Glioblastoma Multiforme | 700 | Dec 2016actual | — | 2017-04-10 |
| Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)NCT02244502Adverse Events Severity and FrequencyOpen-label · Treatment | Phase 1/2 | Unknown status | Device: NovoTTF-100L(O) · Drug: Paclitaxel | Ovarian Carcinoma | 31 | Dec 2016 | — | 2016-09-21 |
| NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung CancerNCT00749346Device related toxicityNon-randomized · Open-label · Treatment | Phase 1/2 | Completed | Device: NovoTTF-100L | Non-small Cell Lung Cancer, NSCLC | 42 | Jul 2011actual | — | 2011-09-27 |
| Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)NCT00379470Overall SurvivalRandomized · Open-label · Treatment | Phase 3 | Completed | Device: NovoTTF-100A | Recurrent Glioblastoma Multiforme | 236 | Nov 2009actual | — | 2012-05-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19